If you have been reading about fatty acid oxidation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-07-26. Numbers and descriptions here follow the published literature rather than marketing material.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a metabolic modulator. |
| Approved medical use | None in major jurisdictions | Not a registered drug. |
| Common test matrix | Urine | Most anti-doping samples use urine. |
| Typical detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Reference standard storage | -20 °C, desiccated | Typical for analytical standards. |
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
Miriam Luke. President, Henley Rowing Club and lately Chair, Henley Women's Regatta. For services to Women's Rowing. Martin Edward Machray. Executive Director of Performance, NHS England, London. For services to Healthcare. Malcolmina Mackay Macleod. Social and Health Carer. For services to the community of North Uist, Scotland. Professor Roma Maguire. Professor of Digital Health and Care, University of Strathclyde. For services to Health Care Research. Helen Ann Maitland. Lately National Director for Urgent and Unscheduled Care, Scottish Government. For services to NHS Scotland. Eric Malcomson. Founder and Chair, Tove Valley Broadband. For services to the community in the Tove Valley, Northamptonshire. Robert James Hammond Malcomson. Deputy Director, Cabinet Office. For public and voluntary service to the LGBTQ+ Community and to Homeless People. Sharon Manning. Cancer Nurse Specialist, Macmillan. For services to Cancer Patient Care. Deirdre Marshall. Team Leader, Ministry of Defence. For services to Defence. Kathryn Julia Marshall. Senior Manager, Lloyds Banking Group, Halifax. For services to Further Education and Skills. Robert James Martin. For services to Drama in Northern Ireland. Elsie Barbara Martlew. Lately Deputy Leader, City of Carlisle Council. For Political and Public Service. Paul Nicholas Martynenko. Vice-President, Registration and Standards, BCS, The Chartered Institute for IT. For services to the Information Technology Industry. Sarah Mason. Chief Executive Officer, Women's Aid Federation Northern Ireland. For services to Women and Girls.
The CDC Good laboratory practice guidelines for newborn screening recommend that "laboratory specimen retention procedures should be consistent with patient decisions." Researchers have described the NBS samples as a gold mine representing a patient population that would otherwise be impossible to get. The American Civil Liberties Union (ACLU), Council for Responsible Genetics(CRG), and the International Association of Privacy Professionals(IAPP) oppose the long term storage of identifiable NBS blood spots. In 2009, the Texas NBS program had to destroy millions of stored blood spots that had been stored for decades without consent. In Michigan, a 2022 lawsuit found that the NBS program long term storage and sales to third-parties was found to violate state statues noting how "post-testing conduct is not necessary to effectuate that interest because 'the health of the child is no longer at stake.'" In New Jersey, the Institute for Justice filed a class-action lawsuit in 2022 under the 4th amendment seeking to limit the retention period of NBS cards after they were found to be used in warrantless law enforcement investigations without consent.
==== Propanephosphonic acid anhydride ==== Since late 2000s, propanephosphonic acid anhydride, sold commercially under various names such as "T3P", has become a useful reagent for amide bond formation in commercial applications. It converts the oxygen of the carboxylic acid into a leaving group, whose peptide-coupling byproducts are water-soluble and can be easily washed away. In a performance comparison between propanephosphonic acid anhydride and other peptide coupling reagents for the preparation of a nonapeptide drug, it was found that this reagent was superior to other reagents with regards to yield and low epimerization.
=== Europe === Following discussions on the safety of certain pharmaceutical products derived from kava and sold in Germany, the EU imposed a temporary ban on imports of kava-based pharmaceutical products in 2002. The sale of kava plant became regulated in Switzerland, France, and in prepared form in the Netherlands. Some Pacific island states, which had been benefiting from the export of kava to the pharmaceutical companies, have attempted to overturn the EU ban on kava-based pharmaceutical products by invoking international trade agreements: Fiji, Samoa, Tonga, and Vanuatu argued at the WTO that the ban was imposed with insufficient evidence. The pressure prompted Germany to reconsider the evidence base for banning kava-based pharmaceutical products. On 10 June 2014, the German Administrative Court overturned the 2002 ban, making selling kava as a medicine legal, albeit strictly regulated; personal possession of kava has never been illegal. In Germany, kava-based pharmaceutical preparations are currently prescription drugs. Furthermore, patient and professional information brochures have been redesigned to warn about potential side effects. These strict measures have been opposed by some of the leading kava scientists. In early 2016, a court case was filed against the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM/German Federal Institute for Drugs and Medical Devices), arguing that the new regulatory regime is too strict and not justified.
== History == The sequence of human GM-CSF was first identified in 1985 and soon three recominbant human GM-CSFs were produced, one in bacteria, one in mammalian cells, and one in yeast; Immunex developed GM-CSF manufactured in yeast into Leukine. Clinical trials of sargramostim were initiated in 1987; in that same year it was administered to six people as part of a compassionate-use protocol for the victims of cesium irradiation from the Goiânia accident. It was approved by the FDA in March 1991, under the brand name Leukine for acceleration of white blood cell recovery following autologous bone marrow transplantation in people with non-Hodgkin's lymphoma, acute lymphocytic leukemia, or Hodgkin's disease. In November 1996, the FDA also approved sargramostim for treatment of fungal infections and replenishment of white blood cells following chemotherapy. A liquid formulation was approved in 1995. Immunex was acquired by Amgen in 2002. As part of the acquisition, Leukine was spun off to Berlex, which became Bayer HealthCare in 2007. In January 2008, Bayer informed healthcare professionals of the market withdrawal of the current liquid formulation of sargramostim. The liquid formulation was withdrawn because of an upward trend in spontaneous reports of adverse reactions, including syncope (fainting), which are temporally correlated with a change that was made to the formulation around April 2007 to include edetate disodium (EDTA). The upward trend in adverse reaction reporting rates had not been observed with the use of lyophilized sargramostim.
Sources: en.wikipedia.org
In each department, in each province of Peru occupied by the Colombians, small dictators exercised their functions, widely empowered to fleece the people (...) Prototype of those little dictators who in 1824 sowed terror in Peru, is that Manterola appointed governor of Huamachuco by Bolívar, who carried out his functions accompanied by his mistress, and at the same time that he looted the unfortunate towns of his jurisdiction and tortured his neighbors." Bolívar was also accused of carrying out a geopolitics with a clear anti-Peruvian direction in Gran Colombia, with absolute opposition to the interests of said political society, both in its form of the Viceroyalty of Peru and of the Republic of Peru, denouncing a mixture of admiration and envy of Peru's economic privileges, as well as suspicion for its population, which he constantly described as contemptuous, even before intervening in its political affairs, since this antipathy would have been clearly distilled since the years of the famous Jamaica Letter. (…) The Viceroyalty of Peru, whose population amounts to a million and a half inhabitants, is undoubtedly the most submissive and from which the most sacrifices have been made for the king's cause, (…) Chile can be free. Peru, on the contrary, contains two enemy elements of every fair and liberal nature: gold and slaves [referring to the Indians]. The first corrupts everything; the second is corrupted by itself. The soul of a servant [referring to the common people of Peru] rarely manages to appreciate healthy freedom; he rages in riots or humbles himself in chains.
=== Adaptation strategies === Potato production is expected to decline in many areas due to hotter temperatures and decreased water availability. Conversely, production is predicted to become possible in high altitude and latitude areas where it has been limited by frost damage, such as in Canada and Russia. This will shift potato production to cooler areas, mitigating much of the projected decline in yield. However, this may trigger competition for land between potato crops and other land uses, mostly due to changes in water and temperature regimes. The other approach is through the development of varieties or cultivars which would be more adapted to altered conditions. This can be done through 'traditional' plant breeding techniques and genetic modification. These techniques allow for the selection of specific traits as a new cultivar is developed. Certain traits, such as heat stress tolerance, drought tolerance, fast growth/early maturation and disease resistance, may play an important role in creating new cultivars able to maintain yields under stressors induced by climate change. For instance, developing cultivars with greater heat stress tolerance would be critical for maintaining yields in countries with potato production areas near current cultivars' maximum temperature limits (e.g. Sub-Saharan Africa, India). Superior drought resistance can be achieved through improved water use efficiency (amount of food produced per amount of water used) or the ability to recover from short drought periods and still produce acceptable yields.
=== Magic numbers === As early as 1914, the possible existence of superheavy elements with atomic numbers well beyond that of uranium—then the heaviest known element—was suggested, when German physicist Richard Swinne proposed that superheavy elements around Z = 108 were a source of radiation in cosmic rays. Although he did not make any definitive observations, he hypothesized in 1931 that transuranium elements around Z = 100 or Z = 108 may be relatively long-lived and possibly exist in nature. In 1955, American physicist John Archibald Wheeler also proposed the existence of these elements; he is credited with the first usage of the term "superheavy element" in a 1958 paper published with Frederick Werner. This idea did not attract wide interest until a decade later, after improvements in the nuclear shell model. In this model, the atomic nucleus is built up in "shells", analogous to electron shells in atoms. Independently of each other, neutrons and protons have energy levels that are normally close together, but after a given shell is filled, it takes substantially more energy to start filling the next. Thus, the binding energy per nucleon reaches a local maximum and nuclei with filled shells are more stable than those without. This theory of a nuclear shell model originates in the 1930s, but it was not until 1949 that German physicists Maria Goeppert Mayer and Johannes Hans Daniel Jensen et al. independently devised the correct formulation. The numbers of nucleons for which shells are filled are called magic numbers.
Cartalax (Ala-Glu-Asp, T-31, AED) is a tripeptide derivative developed in Russia. It has anti-aging effects in vitro and in animal models, and has been sold in Russian-speaking countries as well as more broadly over the internet as a supposed treatment for conditions such as arthritis, though only limited studies in humans have been published.
Sources: en.wikipedia.org
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.
Anti-doping laboratories use LC-MS/MS to detect GW501516 and its metabolites, usually in urine. The method can identify the parent compound at low concentrations. Detection windows vary with dose and individual factors.
No, cardarine has no approved medical uses in major jurisdictions. Early research explored metabolic conditions, but those programs were discontinued. It is not a registered treatment for any disease.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.